COMMON STOCK PURCHASE WARRANT ASSEMBLY BIOSCIENCES, INC.Common Stock Purchase Warrant • June 18th, 2024 • Assembly Biosciences, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Gilead Sciences, Inc. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 18, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Assembly Biosciences, Inc., a Delaware corporation (the “Company”), up to 179,500 shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 18th, 2024 • Assembly Biosciences, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 17, 2024, between Assembly Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc. (including its successors and assigns, the “Purchaser”).
ASSEMBLY BIOSCIENCES, INC. AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • June 18th, 2024 • Assembly Biosciences, Inc. • Pharmaceutical preparations • New York
This Amendment No. 1 to Common Stock Purchase Agreement (this “Amendment”) is dated as of June 17, 2024, by and between Assembly Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Delaware corporation (“Gilead,” and together with the Company, the “Parties”). All capitalized terms not otherwise defined herein shall have the respective meanings set forth in that certain Common Stock Purchase Agreement, dated as of October 15, 2023, by and between the Company and Gilead (the “Agreement”).
ASSEMBLY BIOSCIENCES, INC. AMENDMENT NO. 1 TO INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • June 18th, 2024 • Assembly Biosciences, Inc. • Pharmaceutical preparations • New York
This Amendment No. 1 to Investor Rights Agreement (this “Amendment”) is dated as of June 17, 2024, by and between Assembly Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Delaware corporation (“Gilead,” and together with the Company, the “Parties”). All capitalized terms not otherwise defined herein shall have the respective meanings set forth in that certain Investor Rights Agreement, dated as of October 15, 2023, by and between the Company and Gilead (the “Agreement”).
